On Jun. 24, 2020, Symbiosis Pharmaceutical Services, an India-based specialist provider of pharmaceutical and vaccine development services, announced it had signed a supply agreement with AstraZeneca for sterile manufacture of the COVID-19 recombinant adenovirus vaccine known as AZD1222 for AstraZeneca sponsored clinical trials.

Under the agreement, Symbiosis will provide AstraZeneca fast-track access to sterile vaccine drug product manufacturing capacity at its facility in Stirling, Scotland for the clinical trial supply.